Digestive system

Choludexan and viral hepatitis: what is common?
Published in the journal «District Doctor» October-November’2017
Pathogenetic treatment of patients with chronic viral hepatitis with severe liver fibrosis: aspects of UDCA application
Application of the infusion form of L-carnitine in the complex treatment of patients with stage III chronic kidney disease
Published in the journal «Medical Business» № 1-2’2018
Mitochondrial dysfunction in neurodegenerative disorders: from pathogenesis to therapy
Published in a journal «International Journal of Neurology» Vol 16 № 4’2020
Primary biliary cholangitis: innovation and consistency in the EASL guidelines
Published in a journalе «District doctor» May-June’2017
UDCA and "large" cholestatic liver diseases
Published in the journal «District Doctor» april’2017
«Dissolution» of gall stones: dreams or reality?
Published in a journal «District doctor» мarch’2017
Pathogenetic reasons for use of hepatoprotector with approval clinical efficancy - ursodeoxycholic ACID: from discovery history to evidence base
Published in a journal «District doctor» february’2017
ULSEPAN: pantoprazol 40 mg
Published in the journal «Modern Pharmacy» ’2016
The use of pantoprazole in the prevention of NSAID gastropathy
Published in a journal «District doctor» november’2016

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design